[Vasopressin in the critically ill patient]

Area of Science:

• Endocrinology
• Pharmacology
• Critical Care Medicine

Background:

• Vasopressin (AVP), a posterior pituitary hormone, is recognized for its antidiuretic and potent vasopressive effects.
• AVP's vasopressive activity stems from V1 receptor activation in vascular smooth muscle, making it crucial in critical care.
• Understanding AVP's biochemical and pharmacological profiles is essential for its therapeutic applications.

Purpose of the Study:

• To review the biochemical and pharmacological characteristics of vasopressin (AVP) and its analogues.
• To evaluate the scientific evidence for AVP therapy in vasoplegic shock, comparing its efficacy to norepinephrine.
• To present current and emerging indications for AVP in critically ill patients based on recent studies and guidelines.

Main Methods:

• Literature review of biochemical and pharmacological properties of AVP.
• Analysis of clinical studies and trials investigating AVP in vasoplegic shock.
• Synthesis of data from recent research and international guidelines on AVP indications.

Main Results:

• Vasopressin exhibits strong vasopressive properties through V1 receptor activation.
• Evidence supports AVP as a potential alternative or adjunct to norepinephrine in vasoplegic shock.
• Emerging indications for AVP in critical care are identified based on recent evidence.

Conclusions:

• Vasopressin is a key therapeutic agent in critical care, particularly for vasoplegic shock.
• AVP offers significant vasopressive benefits via V1 receptor stimulation.
• Further research and adherence to guidelines are important for optimizing AVP use in critical care settings.